Comparing survival and treatment response of patients with acquired T790M mutation second‐line osimertinib versus sequential treatment of chemotherapy followed by osimertinib: A real‐world study

Abstract Purpose To investigate the survival benefit with first/second generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) and osimertinib in different treatment sequences. Methods We retrospectively screened 3807 patients diagnosed with cancer between 2013 and 2019 at...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Chin‐Chou Wang, Chien‐Hao Lai, Yu‐Ping Chang, Huang‐Chih Chang, Chia‐Cheng Tseng, Kuo‐Tung Huang, Meng‐Chih Lin
Format: article
Langue:EN
Publié: Wiley 2021
Sujets:
Accès en ligne:https://doaj.org/article/34581f760dc54df492d1a05b4f503c44
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!